v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:        
License and collaboration revenue $ 10,000   $ 11,000 $ 10,000
Total revenue 10,000   11,000 10,000
Operating expenses:        
Research and development 58,474 $ 34,402 181,826 112,343
General and administrative 27,435 13,178 60,092 37,730
Acquired in-process research and development 27,500 5,000 57,500 5,000
Total operating expenses 113,409 52,580 299,418 155,073
Loss from operations (103,409) (52,580) (288,418) (145,073)
Other income (expense), net:        
Interest expense on royalty obligation (7,453) (1,679) (20,553) (1,679)
Interest expense on senior secured term loan (2,058)   (4,146)  
Interest expense on convertible senior notes (1,709)   (3,454)  
Interest income 5,795 2,766 15,416 8,902
Other (expense) income , net (40) (6) (48) 370
Total other income (expense), net (5,465) 1,081 (12,785) 7,593
Loss before income taxes (108,874) (51,499) (301,203) (137,480)
Income tax provision (benefit) 49   163 (185)
Net loss $ (108,923) $ (51,499) $ (301,366) $ (137,295)
Net loss per share - basic (in dollars per share) $ (1.65) $ (1.22) $ (4.91) $ (3.27)
Net loss per share - diluted (in dollars per share) $ (1.65) $ (1.22) $ (4.91) $ (3.27)
Weighted-average common stock outstanding - basic (in shares) 66,147,400 42,159,340 61,416,660 41,943,160
Weighted-average common stock outstanding - diluted (in shares) 66,147,400 42,159,340 61,416,660 41,943,160
Comprehensive loss:        
Net loss $ (108,923) $ (51,499) $ (301,366) $ (137,295)
Other comprehensive income (loss):        
Unrealized (loss) gain on investments (164) 35 (1,285) 77
Foreign currency translation adjustment 45 (10) 89 (340)
Comprehensive loss $ (109,042) $ (51,474) $ (302,562) $ (137,558)